A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas

- Metastatic disease

- Documented disease progression after prior gemcitabine based therapy

- KPS >/= 70

- Adequate bone marrow function

- Adequate hepatic function

- Adequate renal function

Exclusion Criteria:

- Active CNS metastasis

- Clinically significant GI disorders

- Severe arterial thromboembolic events less than 6 months before inclusion

- NYHA Class III or IV congestive heart failure, ventricular arrhythmias or
uncontrolled blood pressure

- Active infection or uncontrolled fever

- Pregnant or breast feeding patients